This decision will contribute to facilitating access to these very popular weight-loss treatments in the United States, which experts consider a major breakthrough in this field.
This technology, originally developed to treat diabetes, relies on mimicking the action of the digestive hormone “GLP-1,” which regulates appetite, and is commercially marketed under the names “Ozempic,” “Wegovy,” and “Zepbound.”
These drugs are usually available as an injectable solution, but are now being developed in pill form for easier administration.
Novo Nordisk stated in its statement that “Wegovy tablets” are “the first oral GLP-1 hormone treatment approved for weight management” in the United States.
U.S. health authorities have previously approved another version of these widespread treatments, but not for the purpose of weight loss.
These treatments, which achieve significant weight loss, have seen widespread demand in recent years, especially in the United States, where about 40% of adults suffer from obesity, a chronic disease.
However, these treatments are not accessible to many patients due to their high price, which can exceed one thousand dollars per month.
